With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.
With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.
Download these slides for expert perspectives on incorporating immune checkpoint inhibitor–based therapy into optimal management of advanced/metastatic TNBC, including the biologic rationale, biomarkers for response, and key trial data.
Download these slides for an expert-curated review of the latest developments in using immune checkpoint inhibitor–based therapy to treat early-stage TNBC, followed by insights into monitoring and management of immune-related adverse events.
Download these slides for expert insights into approved and emerging antibody–drug conjugates for managing TNBC, including sacituzumab govitecan, ladiratuzumab vedotin, and more.
Download this short summary slideset of key takeaways from a CCO live Webinar for an expert overview on incorporating immune checkpoint inhibitors and antibody–drug conjugates into optimal management of early-stage and advanced TNBC.
In this interactive recording of a live CCO Webinar, a dynamic expert panel discusses the latest data on optimal use of immune checkpoint inhibitors and antibody–drug conjugates for treating patients with early-stage through metastatic TNBC.